Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and γ-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.
1 . A pharmaceutical composition comprising:
a first component, wherein the first component is selected from a solution comprising 4-((L-valyl)oxy)butanoic acid and immediate release granules, wherein
the immediate release granules comprise 4-((L-valyl)oxy)butanoic acid; and
the immediate release granules are uncoated or comprise an immediate release coating; and
a second component comprising modified release granules, wherein the modified release granules comprise:
a core comprising 4-((L-valyl)oxy)butanoic acid; and
a modified release coating surrounding the core, wherein
a molar ratio of 4-((L-valyl)oxy)butanoic acid in the first to 4-((L-valyl)oxy)butanoic acid in the second component is from 1:1 to 1:10.
2 . The pharmaceutical composition of claim 1 , wherein the immediate release granules comprise:
greater than 80 wt % of 4-((L-valyl)oxy)butanoic acid;
a binder; and
an antistatic agent.
3 . The pharmaceutical composition of claim 1 , wherein the modified release coating further comprises:
a water soluble polymer;
a water insoluble polymer;
a plasticizer; and
an antistatic agent.
4 . The pharmaceutical composition of claim 1 , wherein the first component is the immediate release granules.
5 . The pharmaceutical composition of claim 1 , wherein
the pharmaceutical composition is a suspension;
the first component is a solution; and
the modified release particles are suspended in the solution.
6 . A pharmaceutical composition comprising:
a first component, wherein the first component is selected from a solution comprising 4-((L-valyl)oxy)butanoic acid and immediate release granules, wherein
the immediate release granules comprise 4-((L-valyl)oxy)butanoic acid; and
the immediate release granules are uncoated or comprise an immediate release coating; and
a second component comprising modified release granules, wherein the modified release granules comprise:
a core comprising 4-((L-valyl)oxy)butanoic acid; and
a modified release coating surrounding the core, wherein
the first component comprises from 5 mol % to 40 mol % of 4-((L-valyl)oxy)butanoic acid;
the second component comprises from 60 mol % to 90 mol % of 4-((L-valyl)oxy)butanoic acid; and
mol % is based on the total moles of 4-((L-valyl)oxy)butanoic acid in the pharmaceutical composition.
7 . The pharmaceutical composition of claim 6 , wherein the immediate release granules comprise:
greater than 80 wt % of 4-((L-valyl)oxy)butanoic acid;
a binder; and
an antistatic agent.
8 . The pharmaceutical composition of claim 6 , wherein the modified release coating further comprises:
a water soluble polymer;
a water insoluble polymer;
a plasticizer; and
an antistatic agent.
9 . The pharmaceutical composition of claim 6 , wherein the first component is the immediate release granules.
10 . The pharmaceutical composition of claim 6 , wherein
the pharmaceutical composition is a suspension;
the first component is a solution; and
the modified release particles are suspended in the solution.
11 . A pharmaceutical composition comprising:
a first component, wherein the first component is selected from a solution comprising 4-((L-valyl)oxy)butanoic acid and immediate release granules, wherein
the immediate release granules comprise 4-((L-valyl)oxy)butanoic acid; and
the immediate release granules are uncoated or comprise an immediate release coating; and
a second component comprising modified release granules, wherein the modified release granules comprise:
a core comprising 4-((L-valyl)oxy)butanoic acid; and
a modified release coating surrounding the core, wherein
the first component comprises from 10 wt % to 50 wt % of 4-((L-valyl)oxy)butanoic acid, and
the second component comprises from 50 wt % to 90 wt % of 4-((L-valyl)oxy)butanoic acid, and
wherein wt % is based on the total weight of 4-((L-valyl)oxy)butanoic acid in the pharmaceutical composition.
12 . The pharmaceutical composition of claim 11 , wherein a weight ratio of 4-((L-valyl)oxy)butanoic acid in the immediate release component to 4-((L-valyl)oxy)butanoic acid in the modified release component is from 1:1.5 to 1:3.5.
13 . The pharmaceutical composition of claim 11 , wherein the modified release coating further comprises:
a water soluble polymer;
a water insoluble polymer;
a plasticizer; and
an antistatic agent.
14 . The pharmaceutical composition of claim 11 , wherein the first component is the immediate release granules.
15 . The pharmaceutical composition of claim 11 , wherein
the pharmaceutical composition is a suspension;
the first component is a solution; and
the modified release particles are suspended in the solution.
16 . A method of treating narcolepsy, cataplexy, excessive daytime sleepiness associated with narcolepsy, excessive daytime sleepiness associated with Parkinson's disease, excessive daytime sleepiness associated with multiple sclerosis, cataplexy associated with narcolepsy, fatigue associated with Parkinson's disease, fatigue associated with multiple sclerosis, fibromyalgia, or idiopathic hypersomnia, in a patient comprising administering to a patient in need of said treatment a therapeutically effective amount of the pharmaceutical composition of claim 1 .
17 . A method of treating narcolepsy, cataplexy, excessive daytime sleepiness associated with narcolepsy, excessive daytime sleepiness associated with Parkinson's disease, excessive daytime sleepiness associated with multiple sclerosis, cataplexy associated with narcolepsy, fatigue associated with Parkinson's disease, fatigue associated with multiple sclerosis, fibromyalgia, or idiopathic hypersomnia in a patient comprising administering to a patient in need of said treatment a therapeutically effective amount of the pharmaceutical composition of claim 6 .
18 . A method of treating narcolepsy, cataplexy, excessive daytime sleepiness associated with narcolepsy, excessive daytime sleepiness associated with Parkinson's disease, excessive daytime sleepiness associated with multiple sclerosis, cataplexy associated with narcolepsy, fatigue associated with Parkinson's disease, fatigue associated with multiple sclerosis, fibromyalgia, or idiopathic hypersomnia in a patient comprising administering to a patient in need of said treatment a therapeutically effective amount of the pharmaceutical composition of claim 11 .